COSCIENS Biopharma Inc.

TSX:CSCI Stock Report

Market Cap: CA$14.0m

COSCIENS Biopharma Management

Management criteria checks 2/4

COSCIENS Biopharma's CEO is Gilles Gagnon, appointed in Jun 2024, has a tenure of less than a year. total yearly compensation is $401.61K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 1.33% of the company’s shares, worth CA$186.73K. The average tenure of the management team and the board of directors is 3.3 years and 0.8 years respectively.

Key information

Gilles Gagnon

Chief executive officer

US$401.6k

Total compensation

CEO salary percentage100.0%
CEO tenureless than a year
CEO ownership1.3%
Management average tenure3.3yrs
Board average tenureless than a year

Recent management updates

Recent updates

We're Hopeful That Aeterna Zentaris (TSE:AEZS) Will Use Its Cash Wisely

May 10
We're Hopeful That Aeterna Zentaris (TSE:AEZS) Will Use Its Cash Wisely

We're Interested To See How Aeterna Zentaris (TSE:AEZS) Uses Its Cash Hoard To Grow

Nov 12
We're Interested To See How Aeterna Zentaris (TSE:AEZS) Uses Its Cash Hoard To Grow

Here's Why We're Not At All Concerned With Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation

Jul 15
Here's Why We're Not At All Concerned With Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation

Companies Like Aeterna Zentaris (TSE:AEZS) Can Afford To Invest In Growth

Mar 29
Companies Like Aeterna Zentaris (TSE:AEZS) Can Afford To Invest In Growth

Reflecting on Aeterna Zentaris' (TSE:AEZS) Share Price Returns Over The Last Five Years

Feb 04
Reflecting on Aeterna Zentaris' (TSE:AEZS) Share Price Returns Over The Last Five Years

CEO Compensation Analysis

How has Gilles Gagnon's remuneration changed compared to COSCIENS Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$402kUS$402k

-US$15m

Sep 30 2024n/an/a

-US$23m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$18m

Dec 31 2023US$649kUS$415k

-US$3m

Sep 30 2023n/an/a

-US$18m

Jun 30 2023n/an/a

-US$17m

Mar 31 2023n/an/a

-US$20m

Dec 31 2022US$658kUS$369k

US$3m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$10m

Dec 31 2021US$99kn/a

-US$8m

Sep 30 2021n/an/a

-US$7m

Jun 30 2021n/an/a

-US$6m

Mar 31 2021n/an/a

-US$7m

Dec 31 2020US$67kn/a

-US$5m

Compensation vs Market: Gilles's total compensation ($USD401.61K) is above average for companies of similar size in the Canadian market ($USD167.93K).

Compensation vs Earnings: Gilles's compensation has been consistent with company performance over the past year.

CEO

Gilles Gagnon (70 yo)

less than a year

Tenure

US$401,610

Compensation

Mr. Gilles R. Gagnon, M.Sc. MBA, ICD D, serves as Director of COSCIENS Biopharma Inc. (formerly known as Aeterna Zentaris Inc.) since June 03, 2024 and had been its Independent Director since January 1, 20...

Leadership Team

NamePositionTenureCompensationOwnership
Gilles Gagnon
Presidentless than a yearUS$401.61k1.33%
CA$ 186.7k
Giuliano La Fratta
Senior VP of Finance & CFO3.3yrsUS$300.20kno data
Michel Regnier
Senior VP & CTOno dataUS$213.98kno data
Michael Teifel
Senior VP of Non-Clinical Development & Chief Scientific Officer3.9yrsUS$126.71kno data
Matthias Gerlach
Senior Vice President Manufacturing and Supply Chain & Head of Productionno dataUS$138.37kno data

3.3yrs

Average Tenure

Experienced Management: CSCI's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gilles Gagnon
President5.3yrsUS$401.61k1.33%
CA$ 186.7k
Genevieve Foster
Independent Directorless than a yearUS$174.51kno data
Gerald Batist
Member of the Scientific Advisory Boardno datano datano data
Hartmut Michel
Member of the Scientific Advisory Boardno datano datano data
Pierre Labbe
Directorless than a yearUS$20.00kno data
Ronald Miller
Independent Chairmanno dataUS$240.33kno data
Marcel Verheij
Member of the Scientific Advisory Boardno datano datano data
Rene De Frydman
Member of the Scientific Advisory Boardno datano datano data
Alan DeCherney
Member of the Scientific Advisory Boardno datano datano data
Klaus H. Diedrich
Member of the Scientific Advisory Boardno datano datano data
Frans M. Debruyne
Member of the Scientific Advisory Boardno datano datano data
Ulf Rapp
Member of the Scientific Advisory Boardno datano datano data

0.8yrs

Average Tenure

Experienced Board: CSCI's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/28 07:14
End of Day Share Price 2025/04/25 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

COSCIENS Biopharma Inc. is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeByron Capital Markets
Douglas LoeCantor Fitzgerald Canada Corporation
Charles DuncanCitizens JMP Securities, LLC